DOCS:NYE-Doximity Inc (USD)

COMMON STOCK | Health Information Services |

Last Closing

USD 61.31

Change

-1.12 (-1.79)%

Market Cap

USD 13.23B

Volume

1.80M

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Doximity, Inc. operates a cloud-based digital platform for medical professionals in the United States. The company's platform provides its members with digital tools built for medicine, that enables its members to collaborate with colleagues, stay up to date with the latest medical news and research, manage their careers and on-call schedules, streamline documentation and administrative paperwork, and conduct virtual patient visits. It primarily serves physicians, nurse practitioners, physician assistants, medical students, pharmaceutical manufacturers, and healthcare systems. The company was formerly known as 3MD Communications, Inc. and changed its name to Doximity, Inc. in June 2010. Doximity, Inc. was incorporated in 2010 and is headquartered in San Francisco, California.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2025-03-18 )

Largest Industry Peers for Health Information Services

Symbol Name Price(Change) Market Cap
SOLV Solventum Corp.

+0.15 (+0.20%)

USD 13.78B
WEAV Weave Communications Inc

-0.33 (-2.88%)

USD 0.83B
AMWL American Well Corp

-0.33 (-4.02%)

USD 0.16B
CTEV Claritev Corporation

-0.05 (-0.25%)

N/A
EVH Evolent Health Inc

+0.15 (+1.50%)

N/A
PHR Phreesia Inc

+0.34 (+1.26%)

N/A
TDOC Teladoc Inc

-0.48 (-5.41%)

N/A
VEEV Veeva Systems Inc Class A

-0.53 (-0.22%)

N/A
FOXO FOXO Technologies Inc.

-0.01 (-5.11%)

N/A

ETFs Containing DOCS

EDOG:LSE Global X Telemedicine & D.. 6.21 % 0.00 %

-0.06 (0%)

USD 0.36M
EDOC:LSE Global X Telemedicine & D.. 6.13 % 0.00 %

-0.07 (0%)

USD 3.99M
EDOC Global X Telemedicine & D.. 6.00 % 0.00 %

-0.23 (0%)

USD 0.04B
DDOC:F Global X Telemedicine & D.. 5.22 % 0.00 %

+0.09 (+0%)

N/A
EDOC:SW Global X Telemedicine & D.. 4.76 % 0.00 %

N/A

N/A
EDOC:AU 4.31 % 0.00 %

N/A

N/A
HDGE:CA Accelerate Absolute Retur.. 4.01 % 0.00 %

-0.08 (0%)

CAD 0.05B
EKG First Trust Nasdaq Lux Di.. 3.83 % 0.00 %

-0.17 (0%)

USD 2.40M
FDOC:LSE 3.79 % 0.00 %

N/A

N/A
FDHT Fidelity Covington Trust .. 3.21 % 0.00 %

-0.23 (0%)

USD 8.72M
FHH:CA First Trust AlphaDEX US H.. 2.86 % 0.77 %

+0.32 (+0%)

CAD 0.01B
FXH First Trust Health Care A.. 2.70 % 0.63 %

-0.53 (0%)

USD 1.01B
LSEQ Harbor ETF Trust 1.79 % 0.00 %

+0.21 (+0%)

USD 0.02B
XITK SPDR® FactSet Innovative.. 1.40 % 0.45 %

-2.39 (0%)

USD 0.09B
BFOR Barron's 400 ETF 0.41 % 0.65 %

-0.59 (0%)

USD 0.14B
FYC First Trust Small Cap Gro.. 0.00 % 0.70 %

-0.82 (0%)

USD 0.48B
FYX First Trust Small Cap Cor.. 0.00 % 0.63 %

-0.39 (0%)

USD 0.96B
JSMD Janus Henderson Small/Mid.. 0.00 % 0.50 %

-0.84 (0%)

USD 0.45B
SMDY 0.00 % 0.00 %

N/A

N/A
FHH-F:CA First Trust AlphaDEX U.S... 0.00 % 0.00 %

N/A

CAD 0.01B
JFWD 0.00 % 0.00 %

N/A

N/A

Market Performance

  Market Performance vs. Industry/Classification (Health Information Services) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 14.83% 100% F 92% A
Dividend Return N/A N/A N/A N/A N/A
Total Return 14.83% 100% F 92% A
Trailing 12 Months  
Capital Gain 115.27% 100% F 98% N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return 115.27% 100% F 98% N/A
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain -0.04% 44% F 31% F
Dividend Return -0.04% 44% F 20% F
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 48.44% 78% C+ 19% F
Risk Adjusted Return -0.08% 44% F 20% F
Market Capitalization 13.23B 75% C 88% B+

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior capital utilization

The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.

Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Superior Earnings Growth

This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.

Superior Revenue Growth

This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.

High Gross Profit to Asset Ratio

This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.